Literature DB >> 7481652

[Hypertrophic obstructive cardiomyopathy: surgical treatment].

H D Schulte1, H Gramsch-Zabel, B Schwartzkopff.   

Abstract

Hypertrophic obstructive cardiomyopathy (HOCM) is an autosomal, dominant inherited disease of the myocardium which leads slowly to increasing subvalvular, septal and left ventricular hypertrophy and deterioration of systolic and diastolic left ventricular compliance. Difficult molecular-genetic investigations localized genetic defects on different chromosomes. The disease is pathological-anatomically characterized by asymmetric subvalvular (aortic) septal hypertrophy and left ventricular outflow tract obstruction resulting in additional left ventricular hypertrophy and dysfunction. Histologically the myocytes are hypertrophied, exhibit atypical branching (disarray), and there is a high amount of interstitial connective tissue. In our biopsy material (from myectomies) dysplasia could be detected in more than 30% of dysplastic intramural arteries with partly extential media. These changes may indicate microcirculatory disturbances resulting in arrhythmias, syncopes, sudden death, and anginal pain on the basis of microcirculatory disturbances and scar development. Today the discussion of DDD-pacemaker therapy has resumed, but one must wait for definite results, especially in patients in whom surgical treatment seems to be the best choice. The indication for surgical treatment, which usually is transaortic subvalvular myectomy (Morrow) and modifications, is very restrictive. Only patients in clinical degree III (NYHA) after long-term medical treatment are candidates for surgery. In some mainly younger patients the indication in lower clinical degrees was accepted because of a family history with sudden death and personal experience of syncope, life-threatening tachycardia, or after resuscitation. In the period 1963 to 1994 466 patients were operated upon. The mean age was 44.9 years (range 3 months to 82 years). Total early mortality was 4.9% (n = 12).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1995        PMID: 7481652

Source DB:  PubMed          Journal:  Schweiz Med Wochenschr        ISSN: 0036-7672


  10 in total

1.  [Transcoronary ablation of septal hypertrophy (TASH): supersedes it the surgery (myectomy)?].

Authors:  H Kuhn; F Gietzen
Journal:  Herz       Date:  1999-12       Impact factor: 1.443

Review 2.  Current status of alcohol septal ablation for patients with hypertrophic cardiomyopathy.

Authors:  H Seggewiss
Journal:  Curr Cardiol Rep       Date:  2001-03       Impact factor: 2.931

3.  One-year follow-up of percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy in 312 patients: predictors of hemodynamic and clinical response.

Authors:  L Faber; D Welge; D Fassbender; H K Schmidt; D Horstkotte; H Seggewiss
Journal:  Clin Res Cardiol       Date:  2007-09-25       Impact factor: 5.460

4.  Catheter-based septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: follow-up results of the TASH-registry of the German Cardiac Society.

Authors:  L Faber; H Seggewiss; F H Gietzen; H Kuhn; P Boekstegers; L Neuhaus; L Seipel; D Horstkotte
Journal:  Z Kardiol       Date:  2005-08

5.  Risk marker profiles in patients treated with percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy.

Authors:  Amelie Burghardt; Frank van Buuren; Zisis Dimitriadis; Tim Grübbel; Hubert Seggewiss; Smita Scholtz; Dieter Horstkotte; Lothar Faber
Journal:  Clin Res Cardiol       Date:  2018-02-16       Impact factor: 5.460

6.  Long-term follow-up after percutaneous septal ablation in hypertrophic obstructive cardiomyopathy.

Authors:  H Seggewiss; A Rigopoulos; D Welge; P Ziemssen; L Faber
Journal:  Clin Res Cardiol       Date:  2007-09-27       Impact factor: 5.460

7.  Survival after transcoronary ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy (TASH): a 10 year experience.

Authors:  Horst Kuhn; Thorsten Lawrenz; Frank Lieder; Christian Leuner; Claudia Strunk-Mueller; Ludger Obergassel; Markus Bartelsmeier; Christoph Stellbrink
Journal:  Clin Res Cardiol       Date:  2007-12-10       Impact factor: 5.460

8.  Medical therapy versus interventional therapy in hypertropic obstructive cardiomyopathy.

Authors:  Hubert Seggewiss
Journal:  Curr Control Trials Cardiovasc Med       Date:  2000

Review 9.  [Clinical picture and therapy of hypertrophic cardiomyopathy].

Authors:  U Gleichmann; H Seggewiss
Journal:  Med Klin (Munich)       Date:  1998-04-15

Review 10.  Percutaneous Septal Ablation in Hypertrophic Obstructive Cardiomyopathy: From Experiment to Standard of Care.

Authors:  Lothar Faber
Journal:  Adv Med       Date:  2014-05-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.